Achieving and maintaining a healthy weight is beneficial for a number of reasons. A healthy weight lowers a person's chance ...

The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

My weight concerns mainly injure my considerable vanity, and I’m not about to outsource my self-esteem issue to Big Pharma if ...

From heart and kidney health to addiction reduction, GLP-1 drugs like Ozempic and Mounjaro may help with more than just ...

Obesity is more than a cosmetic concern. It’s a chronic disease that can be treated with drugs like semaglutide (Wegovy) and ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Mike Plante struggled with his weight for years, but within six months of starting with the injection drug semaglutide, a medication for diabetes that's also being used for weight-loss ... obstructive ...

The U.S. Food and Drug Administration (FDA) has approved Zepbound, a prescription weight-loss medication, as the first drug ...

This time last year, people were still bickering about whether Novo Nordisk's Wegovy and Eli Lilly & Co.'s Zepbound represented a shortcut to losing weight or a medical breakthrough. But with reams of ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.